布地奈德雾化吸入与甲基泼尼松龙静脉滴注治疗COPD的疗效对比

Comparison on the Clinical Effects of Budesonide for Aerosol Inhalation and Methylprednisolone for Intravenous Infusion in the Treatment of COPD

目的对比布地奈德雾化吸入与甲基泼尼松龙静脉滴注治疗慢性阻塞性肺疾病(COPD)的疗效。方法选取2014年3月至2017年3月我院收治的80例COPD患者作为研究对象,随机分为两组各40例, A组给予布地奈德雾化吸入治疗, B组给予甲基泼尼松龙静脉滴注治疗,比较两组的临床疗效、肺功能指标以及不良反应发生情况。结果治疗后, A组和B组的治疗总有效率比较,差异无统计学意义(92.5%vs. 90.0%, P>0.05)。治疗前,两组的肺功能指标比较无显著差异(P>0.05);治疗后,两组的FEV1%预计值、 PaCO_2均显著优于治疗前(P <0.05),但组间差异无统计学意义(P>0.05)。A组的不良反应发生率为7.5%,显著低于B组的25.0%,差异具有统计学意义(P <0.05)。结论布地奈德雾化吸入与甲基泼尼松龙静脉滴注治疗COPD均有显著疗效,但前者安全性更高,可减轻患者的治疗痛苦。

Objective To compare the clinical effects of budesonide for aerosol inhalation and methylprednisolone for intravenous infusion in the treatment of chronic obstructive pulmonary disease （COPD）. Methods 80 cases of COPD patients admitted to our hospital from March 2014 to March 2017 were selected as research objects, and randomly divided into two groups, with 40 cases in each group. Group A was treated with budesonide for aerosol inhalation, while group B was treated with methylprednisolone for intravenous infusion. The clinical curative effect, pulmonary function indicators and incidence of adverse reactions were compared between the two groups. Results After treatment, no statistical difference was found between group A and group B in the total effective rate of treatment （92.5% vs. 90.0%, P〉0.05）. After treatment, both groups had significantly improved FEV,% predicted value and PaCO2 （P 〈0.05）, while no statistical difference was found between two groups in the pulmonary function indicators （P〉0.05）. The incidence of adverse reactions of group A was 7.5%, significantly lowerthan25.0% of group B（P〈0.05）. Conclusions Bothbudesonide for aerosol inhalation and methylprednisolone for intravenous infusion have significant efficacy in the treatment of COPD, but budesonide has higher safety, which can alleviate the treatment pain of patients.